01850nam a2200373Ia 4500001001200000003000600012005001700018007001400035008004100049040005600090043001200146074001900158086002300177099002300200110009800223245022200321246005000543260004200593300002800635336002600663337002700689338003100716500002600747504004100773533009400814500003500908500002500943650001900968650001700987650002901004776020401033776022001237999001901457ocm51932126OCoLC20180312141842.0he bmb024bbca030327s2002    dcu     bb   f000 0 eng d  aFPSbengcFPSdOCLCQdOCLCOdOCLCQdOCLCAdGPOdMvI  an-us---  a1019-B-01 (MF)0 aY 4.C 73/8:107-140  aY 4.C 73/8:107-1401 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health.10aExamining issues related to competition in the pharmaceutical marketplace :ba review of the FTC report, generic drug entry prior to patent expiration : hearing before ... 107th Congress, 2nd session, October 9, 2002.30aGeneric drug entry prior to patent expiration  aWashington, DC :bU.S. G.P.O.,c2002.  aiii, 142 pages ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  a"Serial no. 107-140."  aIncludes bibliographical references.  aMicrofiche.bWashington :cSupt. of Docs., U.S. G.P.O.,d2003.e2 microfiches : negative.  aShipping list no.:2003-0144-M.  aCRDP Program record. 0aGeneric drugs. 0aCompetition. 0aPharmaceutical industry.08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining issues related to competition in the pharmaceutical marketplacew(OCoLC)85278416808iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining issues related to competition in the pharmaceutical marketplacew(DLC) 2003387711w(OCoLC)51543393  c269569d269569